• IDMC recommends continuation of ACTION3 Phase 3 FSGS trial with no changes
• No safety concerns identified, consistent with prior IDMC reviews
• 271 patients enrolled in the trial as of November 18, 2025

Dimerix Limited, a biopharmaceutical company developing innovative therapies for areas with unmet medical needs, has announced the successful completion of the seventh scheduled Independent Data Monitoring Committee (IDMC) review of the ACTION3 Phase 3 clinical trial for its lead product candidate DMX-200 in Focal Segmental Glomerulosclerosis (FSGS). The IDMC, which is responsible for reviewing and evaluating the available study data for participant safety, study conduct, and progress, has recommended the continuation of the clinical trial as planned, with no changes to the design or safety monitoring. This endorsement further validates the emerging strong safety profile of DMX-200 and reinforces its potential as a well-tolerated treatment option in a space where safety remains a key differentiator. As of November 18, 2025, 271 patients (268 adults and 3 pediatric) have been randomized and dosed in the ACTION3 Phase 3 clinical trial. The next scheduled IDMC meeting is planned for the second quarter of 2026.

The successful completion of the IDMC review and the continued enrollment of patients in the ACTION3 Phase 3 trial for DMX-200 in FSGS highlight the potential of this product candidate to offer a differentiated treatment option with a strong safety profile. This positions DMX-200 as a compelling asset in the FSGS treatment landscape, offering meaningful hope to patients with limited options and representing a significant commercial opportunity in an underserved market.